Nutex Health Dual-Listing on Nasdaq Texas
Analysis based on 6 articles · First reported Sep 22, 2026 · Last updated Sep 23, 2026
The dual listing is a minor, company-specific capital-markets event with negligible broader market impact, though it modestly improves Nutex Health's liquidity and regional investor visibility. Market reaction is likely to be limited given the listing is administrative in nature and does not change the company's fundamentals or capital structure.
Nutex Health Inc. (NASDAQ: NUTX) announced on Sept. 22, 2026 that it received approval to dual-list its common stock on Nasdaq Texas. Trading on the Nasdaq Texas venue is expected to commence at the market open on or about Sept. 23, 2026. The company's common stock will continue to trade on the Nasdaq Global Market under its current ticker symbol NUTX. The dual listing does not require any action by existing stockholders, and shares will remain fully fungible across both trading venues. In connection with the dual listing, Nutex Health filed a registration statement on Form 8-A with the United States — United States Securities and Exchange Commission under Section 12(b) of the Securities Exchange Act of 1934. Chairman and CEO Tom Vo said the move expands the company's visibility among regional institutional investors while maintaining the national and international presence of its primary Nasdaq market. Nutex Health is a physician-led healthcare services and operations company headquartered in Houston, Texas, founded in 2011, with 28 hospital facilities in 12 states and a primary care-centric, risk-bearing physician network. It operates through three divisions: Hospital, Population Health Management, and Real Estate.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard